Sava Technologies has announced its first clinical trial results, demonstrating continuous glucose monitoring (CGM) using its proprietary microsensor technology. In a 10-day independent study, 46 participants with type 1 and insulin-dependent type 2 diabetes wore both the Sava sensor and a leading commercial CGM, with performance compared against a YSI (Yellow Springs Instrument) laboratory reference standard. Conducted across sites in Oxford and Cambridge, the study showed comparable accuracy over the full wear period, with only about a 0.8 percentage point difference in mean absolute relative difference (MARD) between the two systems.

Sava’s main differentiator lies in the size of its sensor. Rather than a traditional filament inserted several millimeters under the skin, the company uses microsensors roughly 10 times smaller, designed to reduce tissue disruption while still accessing interstitial fluid. Despite the smaller form factor, accuracy remained stable throughout the 10-day wear, drifting by only around 1.5 percentage points, supporting the technology’s long-term reliability and its potential as a foundation for future multi-analyte sensing.

Sava isn’t the only company investing in the future of CGM tech. Abbott has been working toward multi-analyte sensing, while others like Trinity BioHealth and Biolinq have developed non-invasive glucose monitoring approaches. Do you think Sava’s microsensor approach could be a real challenger to today’s CGMs — let us know what you think in the comments.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.